Sana Saif Ur Rehman

Medicine & Life Sciences

1. Radiosurgery 100%
2. Non-Small Cell Lung Carcinoma 57%
3. Survival 40%
4. Irinotecan 35%
5. Lung Neoplasms 31%
6. Complement C1 24%
7. Orthodontic Brackets 21%
8. Molecular Targeted Therapy 20%
9. Breast Neoplasms 19%
10. Leucovorin 18%
11. Patient Acceptance of Health Care 17%
12. Drug Therapy 16%
13. Sickle Cell Anemia 16%
14. Lung 15%
15. Esophageal Neoplasms 15%
16. Fluorouracil 15%
17. Hematologic Neoplasms 15%
18. Smoking Cessation 15%
19. Therapeutics 15%
20. Disease Management 15%
21. Ambulatory Care 14%
22. Quality Improvement 14%
23. Artifacts 14%
24. Pancreatic Neoplasms 14%
25. DNA Repair 13%
26. Comorbidity 13%
27. Cisplatin 13%
28. Health Care Costs 13%
29. Immunotherapy 13%
30. Critical Care 13%
31. Metals 13%
32. Cost-Benefit Analysis 13%
33. Appointments and Schedules 12%
34. Confidence Intervals 12%
35. Adenocarcinoma 11%
36. Patient Care 11%
37. Chronic Disease 11%
38. Magnetic Resonance Imaging 10%
39. Heart 9%
40. Infections 9%
41. Population 9%
42. Eye 9%
43. Delivery of Health Care 9%
44. Cardiotoxicity 9%
45. Mutation 8%
46. gemcitabine 8%
47. irinotecan sucrosofate 8%
48. Health 7%
49. Orbit 7%
50. Smoking 7%